Andres Madrigal, MD, PhD

Assistant Professor, Clinical
The Ohio State University

Poster(s):

• (G036) Outcomes And Molecular Findings of BPDCN Patients In The Current Era of The First FDA-Approved Toxin-Fused Anti-CD123 Agent Tagraxofusp, A Single Institution Experience
  Friday, November 17, 2023

  9:15 AM – 10:15 AM MST

• (H040) Lymphoplasmacytic Lymphoma With MYD88 And SAMHD1 Co-Mutations
  Friday, November 17, 2023

  9:15 AM – 10:15 AM MST

• (H057) Rare Cases Of Histiocytic Sarcoma With Therapeutically Targetable BRAF V600E Transformed From Low-Grade B-Cell Lymphomas
  Saturday, November 18, 2023

  9:15 AM – 10:15 AM MST